Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer Copenhagen, Denmark

Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small

Denmark, June 23, 2022 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"),

a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it has selected

EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022.

We currently have two product candidates in our DNA technology

platform, EVX-02 and EVX-03. Based on very encouraging results from our pre-clinical studies of EVX-03, we have decided to use this candidate in an upcoming clinical trial in a new indication.

Enhanced DNA technology in EVX-03

optimized with an APC-targeting unit (Antigen-Presenting Cell), which has shown promising pre-clinical data and significant tumor

reduction at very low doses as well as a clear dose-response relationship in all our preclinical models.

Evaxion has decided to continue the development of EVX-03 in patients

with advanced disease and plans to target non-small cell lung cancer (NSCLC) with EVX-03.

"We are very pleased to announce that the data from EVX-03 is

very encouraging on all parameters from anti-tumor effect to immunogenicity. That is why we are moving forward with EVX-03, as we

firmly believe it will be able to make a difference in multiple indications," said CEO Lars Staal Wegner.

Dr. Wegner continues: "In the EVX-03 program, we plan

to target non-small cell lung cancer as a new indication for this technology because of the vast unmet medical needs, a huge market

potential, and the increased potential to demonstrate rapid proof-of-concept in the clinic. We believe that expanding the PIONEER

platform into this new cancer indication will significantly broaden the opportunities for our technology."

Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered

immunotherapies. With our proprietary and scalable AI technology, we decode the human immune system to discover and develop novel immunotherapies

for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including three patient-specific

cancer immunotherapies. It is located in H rsholm, Denmark, with 70 employees.

For more information

Source: Evaxion Biotech

Forward-looking statement

This announcement contains forward-looking statements

that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement

regarding the Company's future operations, plans and objectives are forward-looking statements. Although the Company believes its

expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement

about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements

may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe,"

"expect," "hope," "aim," "intend," "may," "might," "anticipate,"

"contemplate," "continue," "estimate," "plan," "potential," "predict,"

"project," "will," "can have," "likely," "should," "would," "could",

and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such

forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company's financial

condition and need for additional capital; risks associated with the Company's development work; cost and success of the Company's

product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product

developed using the Company's AI platform technology, including the rate and degree of market acceptance of the Company's

product candidates; risks related to the Company's dependence on third parties including for conduct of clinical testing and product

manufacture; risks associated with the Company's inability to enter into partnerships; risks related to government regulation; risks

associated with protection of the Company's intellectual property rights; risks related to employee matters and managing growth;

risks related to the Company's ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19

and its variants such as Delta and Omicron, risks associated with the recent invasion of the Ukraine by Russia and other risks and uncertainties

affecting the Company's business operations and financial condition.

Forward-looking statements are subject to inherent

risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance, or achievements

to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking

statements, as well as risks relating to the Company's business in general, see the risks described in the "Risk Factors"

section included in the Company's Annual Report on Form 20-F filed on March 31, 2022 and the Company's current and

future reports filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained

in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these

forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking

statements, even if new information becomes available in the future.